. . . "1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted"@en . . "Moclobemide"@en . "Approximately 50% (primarily to albumin)"@en . . "Moclobemid"@en . "71320-77-9"@en . "4-Chlor-N-(2-morpholinoethyl)benzamid"@en . "Humans and other mammals"@en . . "A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder."@en . . "For the treatment of depression."@en . . . . . "Food slows absorption a little. Avoid alcohol. Take after meals in order to minimize the risk of interaction with tyramine."@en . "Moclamine"@en . . . . . . . . . . "4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide"@en . . . . . . . . . . . . . " "@en . . "p-Chloro-N-(2-morpholinoethyl)benzamide"@en . "Moclaime"@en . . . "LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures. "@en . . . "Aurorix"@en . . . . "Moclobemide"@en . "Moclamide"@en . . . . . . . "Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration."@en . . . . . . . "The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms."@en . "approved"@en . "4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide"@en . "Moclobemidum"@en . "Moclobemida"@en . . .